Resistin (RETN): Pro-Inflammatory Adipokine and Macrophage-Derived Mediator of Insulin Resistance in Research

# Resistin (RETN): Pro-Inflammatory Adipokine and Macrophage-Derived Mediator of Insulin Resistance in Research

Resistin is a small cysteine-rich peptide that occupies a prominent but contested place in adipokine biology. Identified in 2001 simultaneously by three groups as a factor connecting obesity to insulin resistance, resistin generated substantial controversy because its primary cellular source differs between rodents (adipocytes) and humans (macrophages/monocytes), making mouse model findings difficult to extrapolate to human pathophysiology. Nevertheless, extensive clinical data demonstrate that plasma resistin is elevated in obesity, insulin resistance, type 2 diabetes, metabolic syndrome, and inflammatory diseases, and its TLR4-activating and AMPK-suppressing mechanisms provide biochemically coherent explanations for how it promotes insulin resistance and systemic inflammation.

Discovery and Early Controversy

Resistin was identified in 2001 through three simultaneous publications:

1. Steppan et al. (2001, PMID: 11201732) in Nature named the protein "resistin" (for its ability to confer resistance to insulin) based on its adipocyte expression in mice and ability to impair insulin action. This paper showed resistin was induced in 3T3-L1 adipocytes by differentiation, elevated in genetically obese ob/ob and db/db mice, and that anti-resistin antibodies improved glucose tolerance in obese mice.

3. Holcomb et al. (2000) had earlier characterized a related cysteine-rich protein in adipose tissue without identifying its metabolic role.

Despite this complexity, substantial evidence has accumulated that human resistin, acting primarily as a macrophage/monocyte-derived cytokine elevated by obesity-associated inflammation, promotes insulin resistance and cardiovascular disease through mechanisms that remain clinically relevant.

Gene and Protein Structure

RETN Gene

The human RETN gene is located on chromosome 19p13.3 and encodes a 108-amino acid precursor. After signal peptide cleavage (residues 1-21), the mature resistin protein is 87 amino acids with a molecular weight of approximately 12.5 kDa. The protein is encoded as a monomer but circulates primarily as disulfide-linked multimers: trimers (~37 kDa), hexamers (~75 kDa), and a high-molecular-weight form (~400 kDa, likely 12-mer or higher oligomers). The hexameric form is the predominant circulating structure in human plasma.

The crystal structure of resistin reveals a distinctive architecture:

• •An N-terminal α-helical domain that forms coiled-coil interactions between subunits
• •A C-terminal cysteine-rich "globular head" domain with β-stranded structure
• •Interchain disulfide bonds between Cys26 residues (equivalent in human sequence) creating the trimeric assembly
• •Trimers further associate via N-terminal coiled-coil domains into hexamers

The cysteine-rich globular head domain is conserved within the RELMs (Resistin-Like Molecules) protein family, which includes RELM-α (also called FIZZ1), RELM-β (FIZZ2), and RELM-γ in mice. These related proteins also contribute to inflammatory and metabolic regulation but show different tissue distributions.

Species Differences in Cellular Source

This is the most important biological distinction in resistin research:

Murine resistin: Expressed almost exclusively in adipocytes of white and brown adipose tissue. Expression increases during adipocyte differentiation, correlates strongly with adiposity, and is regulated by PPARγ, dietary fat, and insulin. The adipocyte origin makes murine resistin a true adipokine in the strict sense.

Human resistin: Expressed predominantly in circulating monocytes and tissue macrophages. The primary stimuli for human resistin production are pro-inflammatory signals (LPS, TNF-α, IL-1β, IL-6) rather than adipocyte differentiation signals. While human adipose tissue produces detectable resistin, this is almost entirely from macrophage infiltrates (particularly M1 macrophages), not adipocytes. The human RETN promoter lacks the C/EBP response elements that drive adipocyte-specific expression in mice.

This means that in humans, elevated plasma resistin in obesity reflects primarily the low-grade inflammatory macrophage activation of obese adipose tissue (macrophage infiltration, M1 polarization), rather than a direct adipocyte secretory response to lipid accumulation. The result is similar (elevated plasma resistin in obesity) but through a different mechanism.

Molecular Mechanisms of Insulin Resistance

Human resistin promotes insulin resistance through several interconnected pathways:

TLR4 Activation

Resistin activates TLR4 on macrophages, liver cells, and vascular endothelial cells through a direct binding interaction — resistin acts as an endogenous TLR4 ligand (similar to RBP4 and catestatin at distinct binding modes). TLR4 activation by resistin triggers:

1. MyD88-dependent signaling → NF-κB nuclear translocation → TNF-α, IL-6, IL-1β, MCP-1 production

2. TRIF-dependent signaling → IRF3 activation → type I interferon pathway

3. JNK phosphorylation → IRS-1 Ser307 phosphorylation → PI3K/Akt signal attenuation

The TLR4-JNK-IRS-1 pathway creates a direct link between resistin and peripheral insulin resistance in muscle and liver. NF-κB activation also induces SOCS3 (by IL-6 signaling), providing a STAT3-mediated second pathway for IRS suppression.

Hepatic Glucose Production via AMPK Suppression

Moon et al. (2003, PMID: 12551869) demonstrated that resistin directly suppresses AMPK activity in the liver. AMPK normally inhibits gluconeogenic enzyme expression (PEPCK, G6Pase) through LKB1-AMPK-FOXO1 and AMPK-TORC2/CREB axis effects. By suppressing AMPK:

1. FOXO1 is not phosphorylated (remains nuclear and active)

2. PEPCK and G6Pase transcription increases

3. Hepatic glucose output (glycogenolysis + gluconeogenesis) increases

4. Fasting hyperglycemia worsens

This AMPK suppression explains why resistin infusion in mice raises fasting glucose without impaired insulin secretion — the defect is hepatic insulin resistance (reduced suppression of hepatic glucose production by insulin) rather than peripheral glucose uptake impairment primarily.

Endoplasmic Reticulum Stress Induction

In hepatocytes and adipocytes, resistin has been shown to induce ER stress markers (GRP78/BiP upregulation, CHOP induction, p-eIF2α). ER stress contributes to insulin resistance through IRE1α-JNK and PERK-eIF2α pathways that suppress IRS-1 signaling. Thus resistin through ER stress provides a third, slower-acting mechanism complementing TLR4 and AMPK pathways.

Endothelial Dysfunction

Resistin promotes endothelial dysfunction through several mechanisms:

• •Increases endothelial cell expression of VCAM-1 and ICAM-1 (via NF-κB)
• •Reduces eNOS expression and NO bioavailability
• •Promotes endothelin-1 production
• •Enhances monocyte adhesion to endothelium
• •Increases vascular smooth muscle cell (VSMC) proliferation and migration

These vascular effects connect resistin to atherosclerosis independently of its metabolic insulin-resistance effects.

Regulation of Human Resistin

Human resistin (macrophage-derived) is regulated by:

Pro-inflammatory stimuli (increase resistin):

• •LPS (TLR4 agonist) — potent inducer
• •TNF-α, IL-1β, IL-6 — each individually increases resistin in macrophages
• •Hypoxia: HIF-1α binds RETN promoter and induces expression
• •Free fatty acids (palmitate): TLR4-mediated resistin induction

Anti-inflammatory stimuli (decrease resistin):

• •IL-10: potent suppressor of macrophage resistin
• •Statins (through anti-inflammatory effects)
• •TZDs/PPARγ agonists: suppress macrophage resistin (opposite to their effect in mouse adipocytes)
• •Adiponectin: counter-regulatory, reduces resistin (and vice versa)

Thus in human adipose tissue, the interplay between adiponectin (anti-inflammatory, from adipocytes) and resistin (pro-inflammatory, from macrophages) reflects the M2 vs. M1 macrophage balance that determines adipose tissue inflammatory state.

Clinical Associations

Human plasma resistin (reference range: 5-20 ng/mL in healthy adults, elevated in disease) shows the following associations:

Metabolic Disease

• •Obesity: Positively correlates with BMI, visceral adiposity, macrophage infiltration
• •Insulin Resistance: HOMA-IR positive correlation; elevated in pre-diabetic states
• •Type 2 Diabetes: Significantly higher in T2DM vs. normoglycemic subjects; inversely correlates with insulin sensitivity (MCSI from euglycemic clamp studies)
• •Metabolic Syndrome: Elevated in MetS; each component criterion correlates with higher resistin
• •NAFLD: Elevated in NAFLD; correlates with histological grade; higher in NASH vs. simple steatosis

Cardiovascular Disease

• •Coronary Artery Disease: Independent predictor of CAD presence and severity, after adjusting for traditional risk factors and BMI in several large cohorts
• •Heart Failure: Elevated in HF patients; predicts cardiovascular mortality (CORONA, CHARM trials analyses)
• •Hypertension: Positive correlation with systolic blood pressure; contributes to aldosterone stimulation in some models
• •Stroke: Elevated resistin associates with increased stroke risk in prospective studies

Inflammatory Diseases

• •Rheumatoid Arthritis: Significantly elevated in active RA; correlates with DAS-28 disease activity score; synovial fluid resistin higher than plasma
• •IBD: Elevated in Crohn's disease and ulcerative colitis active flares
• •Sepsis: Dramatically elevated in septic shock; correlates with organ failure scores and mortality
• •COVID-19: Elevated resistin in severe COVID-19; correlates with macrophage activation syndrome features

Other Associations

• •PCOS: Conflicting results; some studies show elevation, others do not
• •Kidney Disease: Elevated in CKD; inversely correlates with GFR; plasma resistin rises as kidney function declines (possibly reduced clearance)
• •Cancer: Elevated in several cancer types (colorectal, breast, prostate); may promote tumor-associated macrophage activity

Research Tools and Experimental Systems

Current Research Frontiers

Resistin as a therapeutic target: Given its clear pro-inflammatory and pro-insulin resistance effects, resistin neutralization is an attractive therapeutic concept. Anti-resistin antibodies have shown efficacy in mouse models, but the species differences (mouse resistin = adipokine; human resistin = macrophage cytokine) complicate the translational path. Anti-human resistin antibodies could potentially reduce macrophage-driven insulin resistance in obese adipose tissue and liver.

Resistin in heart failure with preserved ejection fraction (HFpEF): HFpEF is strongly associated with obesity and inflammation, and resistin is elevated in this condition. The resistin-TLR4-NF-κB axis may contribute to the cardiac inflammation and fibrosis that characterizes HFpEF, making resistin a potential therapeutic target in this difficult-to-treat condition.

Resistin and gut microbiome: The gut microbiome influences macrophage polarization in adipose tissue and liver, and LPS from gut bacteria (leaky gut in obesity) activates TLR4 on macrophages to produce resistin. Resistin then amplifies the systemic inflammatory response, creating a gut-adipose-resistin inflammatory circuit in obese metabolic disease.

RELM family biology: The broader context of resistin within the RELM family (RELM-α, β, γ in mice; resistin as the primary human equivalent) connects it to mucosal immunity, Type 2 inflammation, and helminth infection responses — expanding its biology beyond metabolic disease into immunoparasitology.

Resistin in inflammatory arthritis: The marked elevation of resistin in synovial fluid and serum of RA patients, and its ability to promote synoviocyte and chondrocyte pro-inflammatory activity, position it as a potential target alongside IL-6 and TNF-α biologics for RA therapy.

Conclusion

Resistin illustrates the challenges and rewards of translational adipokine research: the mouse model (adipocyte-derived, obesity-correlated) provided compelling initial evidence for a fat-derived insulin resistance mediator, but the human biology (macrophage-derived, inflammation-correlated) revealed a more complex picture where resistin functions primarily as a macrophage-derived inflammatory cytokine that bridges adipose tissue inflammation to systemic metabolic dysfunction. Its molecular mechanisms — TLR4 activation, AMPK suppression, ER stress induction, and endothelial dysfunction — converge on insulin resistance, hepatic glucose overproduction, and cardiovascular pathology through pathways that are independent of adipocyte biology. The clinical associations with metabolic disease, cardiovascular disease, and inflammatory conditions position resistin as a biomarker of overall inflammatory-metabolic burden. Neutralizing anti-resistin approaches and strategies to reduce macrophage resistin production (via anti-inflammatory interventions, TZDs, statins) represent the translational extensions of this basic biology. Recombinant human resistin (hexameric form), TLR4 reporter cell lines, and human macrophage resistin production assays are the primary research tools for mechanistic investigation.

Key References

2. Savage DB, Sewter CP, Klenk ES, et al. Resistin / Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes. 2001;50(10):2199-2202. PMID: 11574398

3. Fain JN, Cheema PS, Bahouth SW, Lloyd Hiler M. Resistin release by human adipose tissue explants in primary culture. Biochem Biophys Res Commun. 2003;300(3):674-678. PMID: 12507505

4. Moon B, Kwan JJ, Duddy N, et al. Resistin inhibits glucose uptake in skeletal muscle cells and activates NF-kappa B and AMPK. Biochem Biophys Res Commun. 2003;307(2):244-249. PMID: 12859945

5. Lehrke M, Reilly MP, Millington SC, et al. An inflammatory cascade leading to hyperresistinemia in humans. PLoS Med. 2004;1(2):e45. PMID: 15578112

6. Filkova M, Haluzik M, Gay S, Senolt L. The role of resistin as a regulator of inflammation: Implications for various human pathologies. Clin Immunol. 2009;133(2):157-170. PMID: 19740705

10. Rajala MW, Lin Y, Ranalletta M, et al. Cell type-specific expression and coregulation of murine resistin and resistin-like molecule-alpha in adipose tissue. Mol Endocrinol. 2002;16(8):1920-1930. PMID: 12145345

---

This article is intended for Research Use Only (RUO). The information provided describes laboratory research findings and does not constitute medical advice. Resistin and related RELM family proteins are research tools and investigational agents. All research applications must comply with applicable institutional, local, and national regulations.